CD19 and B-cell chronic lymphocytic leukemia: Therefore, to evaluate the effect of IDO1-induced survival on CLL cell sensitivity to ABT-199 treatment, we treated CD19+ cells with Kyn, and then we added or not ABT-199 1 nM.